Treatment with apolipoprotein A-1 mimetic peptide reduces lupus-like manifestations in a murine lupus model of accelerated atherosclerosis.
about
Accelerated atherosclerosis in patients with SLE--mechanisms and managementCardiovascular disease in lupus: insights and updatesRegulation of Adaptive Immunity in Health and Disease by Cholesterol MetabolismApolipoprotein A-I modulates regulatory T cells in autoimmune LDLr-/-, ApoA-I-/- mice.Aortic Atherosclerosis in Systemic Lupus ErythematosusAnion exchange HPLC isolation of high-density lipoprotein (HDL) and on-line estimation of proinflammatory HDLStatin therapy in lupus-mediated atherogenesis: two birds with one stone?Cholesterol-Independent Suppression of Lymphocyte Activation, Autoimmunity, and Glomerulonephritis by Apolipoprotein A-I in Normocholesterolemic Lupus-Prone MiceMarked acceleration of atherosclerosis after Lactobacillus casei-induced coronary arteritis in a mouse model of Kawasaki disease.Dysfunctional high-density lipoprotein and the potential of apolipoprotein A-1 mimetic peptides to normalize the composition and function of lipoproteinsSystemic lupus erythematosus and cardiovascular disease: prediction and potential for therapeutic intervention.Accelerated atherosclerosis in SLE: mechanisms and prevention approaches.HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms.The pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in rheumatologic disorders: a comprehensive review.Apolipoprotein A-I and A-I mimetic peptides: a role in atherosclerosisThe beneficial role of vitamin D in systemic lupus erythematosus (SLE).HDL in innate and adaptive immunity.Why are kids with lupus at an increased risk of cardiovascular disease?Attenuation of Cigarette Smoke-Induced Emphysema in Mice by Apolipoprotein A-1 Overexpression.The 5A apolipoprotein A-I (apoA-I) mimetic peptide ameliorates experimental colitis by regulating monocyte infiltration.Sizing up stability: combination therapy with Apo-AI peptide mimetics and statins in systemic lupus erythematosus-mediated atherosclerosis.Immune modulatory effects of statins.The problem of accelerated atherosclerosis in systemic lupus erythematosus: insights into a complex co-morbidity.
P2860
Q26820245-5D570AD8-E1E1-4F0C-8370-DC26E1DA5398Q27016554-912CEEBC-0D00-4924-A94E-55AC2E9B4399Q28083961-D1B24AF9-F641-4208-9746-5324D05B9E06Q34285479-0A6D0F96-1155-4FB6-9BD3-66B98C789A67Q34938841-9297FCAE-6629-4F41-882C-7D171B36E401Q35114897-676F461F-3A8F-4281-96B9-734C8E84F9C7Q35835877-45934B26-FF6B-43D6-B8CE-1DB00F17EBD0Q36260399-B71E5E00-AF04-4E3D-82FC-C7838DC5913DQ36344968-E0436B58-D0DA-4304-9B2B-E3450AE98EB8Q36763561-F4718430-3980-40D6-88B7-ECCD1413208BQ37033345-88498383-1418-4C94-98A6-7FA047BAB9DEQ37658524-8885F296-F9E1-4D4D-93C2-1CFEEE88F062Q37838234-3B51E8DD-C9F6-409F-8460-095FA6FEA7D6Q37909189-DEAF7074-0142-4087-BFF9-E193B068D5A4Q37957869-57E9C9AB-569C-4911-9DC0-01A4ADAAAA7EQ38026775-A11CAEAB-3415-4ABF-8145-73D5F91935DEQ38220759-E38E8F01-9A74-4B04-B57B-CB2F96FE170DQ38591752-4170CE1E-33C2-4EA4-9127-3E1FA8949FC5Q38862679-E4C93E96-B3A8-4314-A60C-508BBCE85D90Q41341405-18457E0A-1C26-43BA-BC25-437B563B6763Q42345718-4306BD58-4314-4A4C-8A38-B8DA34851871Q50214328-562B900A-18D4-4E9A-9A61-99F4B9E75E89Q50417164-03252AC4-1154-447D-AB2D-A3622A735BEB
P2860
Treatment with apolipoprotein A-1 mimetic peptide reduces lupus-like manifestations in a murine lupus model of accelerated atherosclerosis.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Treatment with apolipoprotein ...... f accelerated atherosclerosis.
@ast
Treatment with apolipoprotein ...... f accelerated atherosclerosis.
@en
Treatment with apolipoprotein ...... f accelerated atherosclerosis.
@nl
type
label
Treatment with apolipoprotein ...... f accelerated atherosclerosis.
@ast
Treatment with apolipoprotein ...... f accelerated atherosclerosis.
@en
Treatment with apolipoprotein ...... f accelerated atherosclerosis.
@nl
prefLabel
Treatment with apolipoprotein ...... f accelerated atherosclerosis.
@ast
Treatment with apolipoprotein ...... f accelerated atherosclerosis.
@en
Treatment with apolipoprotein ...... f accelerated atherosclerosis.
@nl
P2093
P2860
P356
P1476
Treatment with apolipoprotein ...... f accelerated atherosclerosis.
@en
P2093
Alan M Fogelman
Antonio La Cava
Betty P Tsao
Casey Van Dyck
Hongyun Li
Jennifer M P Woo
Krystal M T Woo
Lawrence W Castellani
Mohamad Navab
P2860
P2888
P356
10.1186/AR3020
P577
2010-05-18T00:00:00Z
P5875
P6179
1002187603